Zofenopril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Zofenopril
Accession Number
DB13166
Description

Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 429.55
Monoisotopic: 429.106850573
Chemical Formula
C22H23NO4S2
Synonyms
  • Zofenil
  • Zofénopril
  • Zofenopril
  • Zofenoprilum

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Zofenopril.
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Zofenopril.
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Zofenopril.
Acetylsalicylic acidThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid.
Agrostis gigantea pollenThe risk or severity of adverse effects can be increased when Zofenopril is combined with Agrostis gigantea pollen.
Agrostis stolonifera pollenThe risk or severity of adverse effects can be increased when Zofenopril is combined with Agrostis stolonifera pollen.
AlclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alclofenac is combined with Zofenopril.
AldesleukinAldesleukin may increase the hypotensive activities of Zofenopril.
AlfentanilAlfentanil may decrease the antihypertensive activities of Zofenopril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Zofenopril.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Zofenopril calcium88ZQ329PU281938-43-4NSYUKKYYVFVMST-LETVYOFWSA-L
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BIFRIL PLUS 30/12.5 MG FILM TABLET, 28 ADETZofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg)Tablet, film coatedOralULAGAYLAR İLAÇ SAN.VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIFRIL PLUS 30/12.5 MG FILM TABLET, 84 ADETZofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg)Tablet, film coatedOralULAGAYLAR İLAÇ SAN.VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
ZOPROTEC PLUS 30/12.5 MG FILM TABLET, 28 ADETZofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg)Tablet, film coatedOralMENARİNİ İLAÇ SANAYİ VE TİCARET A.Ş.2020-08-14Not applicableTurkey flag
ZOPROTEC PLUS 30/12.5 MG FILM TABLET, 84 ADETZofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg)Tablet, film coatedOralMENARİNİ İLAÇ SANAYİ VE TİCARET A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
C09BA15 — Zofenopril and diureticsC09AA15 — Zofenopril
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Thiobenzoic acids and derivatives / Benzoic acids and derivatives / Thiophenol ethers / Pyrrolidine carboxylic acids / Benzoyl derivatives / N-acylpyrrolidines / Alkylarylthioethers / Tertiary carboxylic acid amides / Thioesters
show 10 more
Substituents
Alkylarylthioether / Aromatic heteromonocyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzoic acid or derivatives / Benzoyl / Carbonyl group / Carbothioic s-ester / Carboxamide group
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
thioester, aryl sulfide, N-acyl-L-amino acid, L-proline derivative (CHEBI:78539)

Chemical Identifiers

UNII
290ZY759PI
CAS number
81872-10-8
InChI Key
IAIDUHCBNLFXEF-MNEFBYGVSA-N
InChI
InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1
IUPAC Name
(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylic acid
SMILES
C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1

References

General References
  1. Nilsson P: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:25-30. [PubMed:18046976]
  2. Mallion JM: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:13-8. [PubMed:18046974]
  3. AIFA Product Information: Bifril (zofenopril calcium) film-coated tablets [Link]
KEGG Drug
D08688
PubChem Compound
92400
PubChem Substance
347829273
ChemSpider
83422
BindingDB
50084629
RxNav
39990
ChEBI
78539
ChEMBL
CHEMBL331378
ZINC
ZINC000003775162
Wikipedia
Zofenopril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4RecruitingTreatmentCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral
TabletOral
Tablet, film coatedOral7.5 mg
Tablet, film coatedOral
Tablet, coatedOral
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00311 mg/mLALOGPS
logP3.64ALOGPS
logP4.31ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.5ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.68 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity116.82 m3·mol-1ChemAxon
Polarizability46.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Ambrosioni E: Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7(1):17-24. [PubMed:17355163]

Drug created on February 11, 2017 15:59 / Updated on February 21, 2021 18:54